Copyright
©The Author(s) 2021.
World J Methodol. Jul 20, 2021; 11(4): 187-198
Published online Jul 20, 2021. doi: 10.5662/wjm.v11.i4.187
Published online Jul 20, 2021. doi: 10.5662/wjm.v11.i4.187
Intervention | Clinical parameters evaluated | ||||||||
Ref. | Creatinine (mg/dL) | Change in BUN (mg/dL) | Cystatin C (mg/L) | Weight loss (kg) | Cumulative urine volume (mL) | ||||
Baseline | Mean changes | Baseline | Mean changes | Baseline | Mean changes | Mean changes | |||
Nesiritide | Owan et al[10], 2008 | 1.85 ± 0.71 | 0.04 ± 0.44 | 44.8 ± 23.3 | -1.3 ± 12.8 | NA | NA | -2.75 ± 3.27 | NA |
Owan et al[10], 2008 (placebo) | 1.65 ± 0.42 | 0.09 ± 0.25 | 38.3 ± 16.6 | 2.4 ± 6.8 | NA | NA | -4.25 ± 3.42 | NA | |
Chen et al[13], 2013 | 1.65 | 0.02 | NA | NA | 1.66 | 0.07 | NA | 8574 | |
Chen et al[13], 2013 (placebo) | 1.70 | 0.02 | NA | NA | 1.86 | 0.11 | NA | 8296 |
- Citation: Ong LT. Evidence based review of management of cardiorenal syndrome type 1. World J Methodol 2021; 11(4): 187-198
- URL: https://www.wjgnet.com/2222-0682/full/v11/i4/187.htm
- DOI: https://dx.doi.org/10.5662/wjm.v11.i4.187